Indian Pharma Q3 Preview: Analysts See Domestic Formulations, US Shortage Driving Growth
The Indian pharmaceutical sector is anticipated to witness robust growth in the third quarter of the fiscal 2025, driven by a combination of factors. Among them is the depreciation in the Indian rupee, which is expected to help companies' US business.
Key drivers of growth include:
Domestic Formulations: Strong growth is expected in key therapeutic areas like cardiac, gastrointestinal, and anti-diabetes.
US Market: Niche launches, easing pricing pressures, and a favourable exchange rate (INR depreciation) are expected to boost US sales.
Drug Shortages: Ongoing shortages in the US are expected to continue to support growth for certain companies.
Nuvama Research expects revenue, Ebitda, and profit after tax of their coverage universe to grow 8%, 10%, and 10% YoY, respectively.
While Axis Securities anticipates revenue growth of 8.1% YoY and 0.9% QoQ for the sector, driven by domestic formulations and niche launches in the US market.
Centrum Broking expects the pharma companies under its coverage to post sales growth of 10% YoY, led by steady growth in domestic formulations and stable pricing in the US.
US Market Shows Resilience
Despite pricing pressures, the US market is projected to exhibit stable growth, supported by the launch of new niche products and ongoing drug shortages.
The US is likely to clock 5% YoY growth with price erosion in mid-single digits, according to Nuvama Research.
Axis Securities anticipates low single-digit growth in the US market, led by volume growth in existing products and the launch of new products.
Company-Specific Highlights
Sun Pharmaceuticals Industries is expected to deliver strong growth in both the US and domestic markets, driven by its specialty portfolio, according to Centrum Broking.
Dr. Reddy's is anticipated to benefit from its strong domestic presence and the continued contribution of its gRevlimid sales, Axis Securities said.
Centrum sees Cipla facing challenges due to supply constraints in Lanreotide, but is expected to benefit from new launches in the US.
While, Lupin is expected to benefit from the launch of gMyrbetriq 50mg in the US, Nuvama Research said.
The brokerage expects Aurobindo to see YoY decline in its US business, due to lower gRevlimid and lower Unit-III contribution.
Divis Laboratories is expected to report revenue growth of 20% YoY with margins at 30.5%, Nuvama Research said.
While, it expects Torrent Pharmaceuticals to report margins at 32% due to a strong branded business.
Biocon is projected to report revenue growth of 15% YoY, but margins are expected to contract YoY/QoQ, Nuvama Research said.
Challenges And Outlook
Pricing Pressures: Despite easing in the US, pricing pressures remain a concern for the sector.
Competition: Intense competition from generic players and increasing regulatory scrutiny continue to pose challenges.
Margins: While expected to remain relatively stable, margin pressure may be experienced by some companies, due to factors like increased R&D expenditure and competition.
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
